Clinical trial
Efficacy and Safety of IVIG-L in ITP Patients
NCT00151840 · Prothya Biosolutions, Industry · Completed
Key facts
| NCT number | NCT00151840 |
|---|---|
| Title | Efficacy and Safety of IVIG-L in ITP Patients |
| Official title | Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients |
| Lead sponsor | Prothya Biosolutions, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopenic, Idiopathic |
| Intervention type | Drug |
| Interventions | IVIG-L |
| Enrollment | 20 |
| Start date | Oct 1, 2001 |
| Completion | Mar 1, 2002 |
| First posted | Sep 9, 2005 |
| Last update posted | Jan 31, 2006 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: